Cabozantinib

證據等級: L5

預測適應症: 10 個

Cabozantinib: From Renal Cell Carcinoma to Liposarcoma

One-Sentence Summary

Cabozantinib is a multi-target tyrosine kinase inhibitor (MET/VEGFR1-3/RET/AXL/KIT) already approved internationally for renal cell carcinoma and other cancers, though it is not yet marketed in Taiwan. The TxGNN model predicts potential efficacy in Liposarcoma, currently supported by 1 clinical trial and 1 publication.

Quick Overview

Item	Content
Original Indication	Renal Cell Carcinoma (and other internationally approved oncology indications; not yet licensed in Taiwan)
Predicted New Indication	Liposarcoma
TxGNN Prediction Score	99.83%
Evidence Level	L2
Taiwan Market Status	✗ 未上市 (Not Marketed)
Number of Authorizations	0
Recommended Decision	Hold (Research Question)

Why is This Prediction Reasonable?

Cabozantinib is a multi-target tyrosine kinase inhibitor that blocks MET, VEGFR1-3, RET, AXL and KIT, thereby suppressing tumour angiogenesis and invasive signalling. This mechanism underlies its established efficacy in renal cell carcinoma, where VEGF/MET-driven vascular signalling is a key oncogenic driver.

Soft tissue sarcomas, including liposarcoma, are also highly dependent on tumour angiogenesis for growth. TxGNN's prediction is mechanistically plausible because cabozantinib's VEGFR2 inhibition can block the vascular supply these tumours rely on, and a subset of liposarcomas has been reported to show upregulated MET expression — providing a secondary mechanistic rationale.

That said, liposarcoma is not a core indication in cabozantinib's original development programme, and current evidence comes from a broader soft-tissue-sarcoma trial rather than a liposarcoma-specific study, so the mechanistic link remains supportive rather than confirmatory.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT05836571	Phase 2	Active, not recruiting	66	Randomized trial comparing ipilimumab + nivolumab alone vs. combined with cabozantinib in advanced soft tissue sarcoma; liposarcoma is among the eligible subtypes but not the sole focus, and results are not yet mature

Literature Evidence

PMID	Year	Type	Journal	Key Findings
41770651	2026	Phase 1	American Journal of Clinical Oncology	Neoadjuvant cabozantinib combined with radiation therapy in extremity soft tissue sarcomas; establishes safety of the combination (prior concern was fistula/perforation risk with concurrent RT), supporting activity across multiple STS subtypes

Taiwan Market Information

Cabozantinib currently holds no marketing authorizations in Taiwan (0 licenses on record; market status: 未上市). No product name, dosage form, or approved indication text is available from Taiwan regulatory data at this time.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (multi-kinase inhibitor: MET/VEGFR1-3/RET/AXL/KIT)
Myelosuppression Risk	Low to moderate — typical for VEGFR-targeted TKIs rather than classic cytotoxic chemotherapy; drug-specific haematologic toxicity data not yet available (see safety data gap below)
Emetogenicity Classification	Low
Monitoring Items	Blood pressure, liver and renal function, urinalysis (proteinuria), wound healing status, CBC
Handling Protection	Oral targeted agent — standard institutional precautions for oral antineoplastic handling apply; drug-specific TFDA handling requirements are not yet confirmed

Safety Considerations

Detailed key warnings, contraindications, and drug interaction data are not yet available from TFDA sources (blocking data gap — see Conclusion). Based on the drug class and evidence referenced elsewhere in this evaluation, known class-level concerns for cabozantinib include hypertension, bleeding risk, and impaired wound healing, which should be verified against the official package insert once available.

Please refer to the package insert for complete safety information.

Conclusion and Next Steps

Decision: Hold (Research Question)

Rationale: Evidence for the liposarcoma indication currently consists of one ongoing, not-yet-mature Phase 2 trial (broader soft-tissue-sarcoma population, not liposarcoma-specific) and one Phase 1 safety study — corresponding to evidence level L2 and decision stage S1. This is preliminary rather than actionable evidence, and a blocking safety gap prevents a full initial safety assessment.

To proceed, the following is needed:

TFDA package insert (warnings/contraindications) — currently blocking, required before any S1 safety evaluation (DG001)
Confirmed mechanism-of-action data from DrugBank to strengthen the mechanistic rationale (DG002)
Mature, subtype-specific results from NCT05836571 or a liposarcoma-focused trial
Clarification of Taiwan regulatory/licensing pathway, since cabozantinib is not currently marketed in Taiwan
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.